Black Diamond Therapeutics, Inc.BDTXNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank38
3Y CAGR-19.6%
5Y CAGR-7.0%
Year-over-Year Change
Research and development spending
3Y CAGR
-19.6%/yr
vs +74.5%/yr prior
5Y CAGR
-7.0%/yr
Recent deceleration
Acceleration
-94.1pp
Decelerating
Percentile
P38
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
4 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $33.49M | -34.7% |
| 2024 | $51.31M | -12.9% |
| 2023 | $58.91M | -8.6% |
| 2022 | $64.44M | -33.5% |
| 2021 | $96.83M | +100.9% |
| 2020 | $48.21M | +121.6% |
| 2019 | $21.75M | +213.0% |
| 2018 | $6.95M | +101.3% |
| 2017 | $3.45M | - |